Form 4: CRISPR Therapeutics Executive Granted Stock Options and Restricted Stock Units

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, received stock options for 33,333 common shares and 25,000 restricted stock units on March 20, 2024.

Summary

• On March 20, 2024, James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, was granted stock options and restricted stock units.
• The stock options grant covers 33,333 common shares with an exercise price of $72.94.
• These options vest in 48 equal monthly installments starting April 20, 2024.
• Kasinger also received 25,000 restricted stock units, each representing a contingent right to receive one share of CRSP common stock.
• The restricted stock units vest in four equal installments on March 20 of 2025, 2026, 2027, and 2028.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the executive.

Future Outlook

The vesting schedules for the stock options and restricted stock units suggest a long-term commitment from the executive.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. Companies like Intellia Therapeutics and Editas Medicine also use similar compensation packages.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice in the biotech industry to incentivize performance and retain key personnel.
• Companies like Intellia Therapeutics and Editas Medicine, which are direct competitors of CRISPR Therapeutics, also utilize similar equity-based compensation structures for their executives.
• The vesting schedules (monthly for options, annually for RSUs) are fairly typical, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates